C
Chemomab Therapeutics Ltd. (CMMB)
NCM – Real Time Price. Currency in USD
1.77
-0.06 (-3.28%)
At close: May 12, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.77
-0.06 (-3.28%)
At close: May 12, 2026, 4:00 PM EDT
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis. The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
| Name | Position |
|---|---|
| Dr. Adi Mor George Ph.D. | Co-Founder, Chief Scientific Officer, CEO & Executive Director |
| Dr. David M. Weiner M.B.A., M.D. | Interim Chief Medical Officer |
| Mr. Jack Lawler | Chief Development Officer |
| Ms. Sigal Fattal CPA, M.B.A. | Chief Financial Officer |
| Date | Type | Document |
|---|---|---|
| 2026-05-06 | 6-K | zk2635214.htm |
| 2026-04-28 | 6-K | zk2635146.htm |
| 2026-03-23 | 20-F | zk2634510.htm |
| 2026-03-19 | 6-K | zk2634872.htm |
| 2025-11-21 | 6-K | zk2534057.htm |
| 2025-08-22 | 6-K | zk2533691.htm |
| 2025-08-14 | 6-K | zk2533584.htm |
| 2025-07-25 | 6-K | zk2533479.htm |
| 2025-07-01 | 6-K | zk2533404.htm |
| 2025-05-27 | 6-K | zk2533263.htm |